ST. LOUIS, Nov 17, 2018 /PRNewswire/ --

​

Direct Biologics, LLC Has Acquired Paisley Laboratories

 

Direct Biologics, LLC announces the acquisition of Paisley Laboratories, LLC. The mission of these combined research and development companies is to transform regenerative healing with an emphasis on improved patient care. Direct Biologics is focused on optimizing the regenerative potential of its unique technologies as an industry leader in providing innovative tissue-based technologies for stimulating regeneration across various applications in orthopedics, plastic surgery, general surgery, podiatry, and more. The acquisition of Paisley Laboratories, LLC expands their ability to develop innovative and revolutionary products based on utilizing human mesenchymal stem cells.

Go to DIRECTBIOLOGICS.COM to learn more.

ABOUT DIRECT BIOLOGICS: Direct Biologics, LLC, headquartered in St. Louis, MO, is a marketleading innovator and science-based manufacturer of regenerative medical products, including a robust line of biologic and kyphoplasty products. Direct Biologics was created to expand the science of cutting-edge biologic technologies through research and commercialization of medical devices and the naturally occurring proteins from allograft tissue compliant with FDA standards for 361 HCT/P products. Current commercial products include, but are not limited to, AmnioFlo and XoFlo products.

ABOUT PAISLEY LABORATORIES:

Paisley Laboratories is headquartered in La Costa, California with laboratories nearby and a cGMP manufacturing facility in Florida. They have extensive intellectual property surrounding proprietary methods for obtaining concentrated growth factors and exosomes from human mesenchymal stem cells and their utility.

SOURCE Direct Biologics
Related Links: https://www.directbiologics.com